These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31578499)

  • 1. Biotech giant helps itself without swallowing Galapagos whole.
    Senior M
    Nat Biotechnol; 2019 Oct; 37(10):1104-1105. PubMed ID: 31578499
    [No Abstract]   [Full Text] [Related]  

  • 2. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 3. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 4. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 5. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 6. Genzyme-Sanofi buy out is second largest biotech deal ever.
    Ratner M
    Nat Biotechnol; 2011 Apr; 29(4):293-4. PubMed ID: 21478828
    [No Abstract]   [Full Text] [Related]  

  • 7. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 9. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 10. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 11. From the analyst's couch: The outlook for biotech exits.
    Grimaldi A
    Nat Biotechnol; 2014 Mar; 32(3):227-8. PubMed ID: 24727772
    [No Abstract]   [Full Text] [Related]  

  • 12. Cheap at any price?
    Ledford H
    Nature; 2007 May; 447(7141):131. PubMed ID: 17495898
    [No Abstract]   [Full Text] [Related]  

  • 13. What mergers can do for you.
    Acharya A
    Nat Biotechnol; 2011 Jun; 29(6):477-9. PubMed ID: 21796820
    [No Abstract]   [Full Text] [Related]  

  • 14. AbbVie buys last available priority voucher for $350 million.
    Morrison C
    Nat Biotechnol; 2015 Nov; 33(11):1120. PubMed ID: 26544127
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech industry faces new bottleneck.
    Garber K
    Nat Biotechnol; 2001 Mar; 19(3):184-5. PubMed ID: 11231516
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech boot camp.
    Ledford H
    Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
    [No Abstract]   [Full Text] [Related]  

  • 17. Japan Biotech Forum: London 2010.
    Al-Shamahi A
    IDrugs; 2010 Nov; 13(11):756-8. PubMed ID: 21046519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-quarter biotech job picture.
    Francisco M
    Nat Biotechnol; 2012 Aug; 30(8):803. PubMed ID: 22871722
    [No Abstract]   [Full Text] [Related]  

  • 19. Genzyme and Isis strike megadeal.
    Mack GS
    Nat Biotechnol; 2008 Mar; 26(3):251-3. PubMed ID: 18327216
    [No Abstract]   [Full Text] [Related]  

  • 20. Roche chases stake in medical sequencing.
    Hayden EC
    Nature; 2012 Apr; 484(7393):152. PubMed ID: 22498604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.